Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P220026/S017

Symplicity Spyral Renal Denervation System

Medtronic, Inc. · Decision date Jul 16, 2026

FDA DECISIONP220026/S017

What did the FDA approve?

FDA records P220026/S017 as a supplement to PMA P220026, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Jul 16, 2026.

FDA approval order statement

approval for the Symplicity G3 Generator to use updated software version v2.04.00.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Jul 16, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P220026/S017
Regulatory pathway
PMA supplement
Product code
QYI
Decision code
APPR
Decision date
Jul 16, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Ablation catheter, renal denervation.

Product code
QYI
FDA device class
3

For the original device and its historical approval scope, see PMA P220026. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P220026 · Original PMA

    Symplicity Spyral Renal Denervation System

  2. P220026/S015 · Related supplement

    Symplicity Spyral Multi-Electrode Renal Denervation Catheter

  3. P220026/S016 · Related supplement

    Symplicity Spyral Renal Denervation Catheter

  4. P220026/S017 received

    Application receipt date recorded by FDA.

  5. P220026/S017 · FDA decision

    Real-Time Process

  6. P220026/S014 · Related supplement

    Symplicity Spyral Renal Denervation System

  7. P220026/S019 · Related supplement

    Symplicity G3 Renal Denervation RF Generator

Timeline entries are records held by MedtechLedger for P220026. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220026

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA approvalNov 17, 2023FDA
Medtronic, Inc.PMA supplementFeb 27, 2026FDA
Medtronic, Inc.PMA supplementMar 25, 2026FDA
Medtronic, Inc.PMA supplementSep 10, 2026FDA
Medtronic, Inc.PMA supplementOct 23, 2026FDA

Explore the linked device profile

Other records with product code QYI

Product / regulatory recordCompanyPathwayDecision dateSource
Recor Medical, Inc.PMA supplementAug 13, 2026FDA
Recor Medical, Inc.PMA supplementJul 29, 2026FDA
Recor Medical, Inc.PMA supplementSep 11, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
3576 Unocal Pl., Santa Rosa, CA, 95403

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records